19.19
price up icon28.36%   4.24
after-market Dopo l'orario di chiusura: 19.01 -0.18 -0.94%
loading
Precedente Chiudi:
$14.95
Aprire:
$15.5
Volume 24 ore:
1.35M
Relative Volume:
5.04
Capitalizzazione di mercato:
$307.78M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+11.57%
1M Prestazione:
+12.82%
6M Prestazione:
-16.05%
1 anno Prestazione:
-52.76%
Intervallo 1D:
Value
$14.65
$21.19
Intervallo di 1 settimana:
Value
$14.65
$21.19
Portata 52W:
Value
$6.875
$74.49

Neurogene Inc Stock (NGNE) Company Profile

Name
Nome
Neurogene Inc
Name
Telefono
(877) 237-5020
Name
Indirizzo
535 W 24TH STREET, NEW YORK
Name
Dipendente
107
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
NGNE's Discussions on Twitter

Confronta NGNE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
NGNE
Neurogene Inc
19.19 307.78M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Neurogene Inc Stock (NGNE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-16 Downgrade Robert W. Baird Outperform → Neutral
2024-06-27 Iniziato BMO Capital Markets Outperform
2024-06-11 Iniziato Robert W. Baird Outperform
2024-04-29 Iniziato Leerink Partners Outperform
2024-03-21 Iniziato William Blair Outperform
2024-01-08 Iniziato H.C. Wainwright Buy
2024-01-05 Iniziato Stifel Buy
2024-01-04 Iniziato TD Cowen Outperform
Mostra tutto

Neurogene Inc Borsa (NGNE) Ultime notizie

pulisher
Jun 18, 2025

Craig-Hallum bullish on Neurogene, initiates with a Buy - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Neurogene (NASDAQ:NGNE) Coverage Initiated by Analysts at Craig Hallum - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Neurogene (NGNE) Receives New Buy Rating from Craig-Hallum | NGN - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neurogene (NGNE) Gains Attention with Promising Gene Therapy for - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neurogene (NGNE) Receives Positive Coverage with a $50 Price Tar - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neurogene (NGNE) Gains Attention with Promising Gene Therapy for Rett Syndrome | NGNE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 14, 2025

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

BMO Capital Markets Issues Positive Forecast for Neurogene (NASDAQ:NGNE) Stock Price - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

Neurogene’s (NGNE) Outperform Rating Reaffirmed at BMO Capital Markets - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Neurogene (NGNE) Price Target Raised by BMO Capital | NGNE Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Neurogene Approves Amendments at Annual Stockholders Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 11, 2025

Neurogene price target raised to $26 from $22 at BMO Capital - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Neurogene Inc. (NASDAQ:NGNE) Receives $44.60 Consensus PT from Brokerages - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Two Sigma Investments LP Invests $472,000 in Neurogene Inc. (NASDAQ:NGNE) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Neurogene Highlights Gene Therapy Advancements in New Update - TipRanks

Jun 09, 2025
pulisher
Jun 08, 2025

Neurogene Inc. (NASDAQ:NGNE) Stock Position Lifted by Wellington Management Group LLP - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph

Jun 06, 2025
pulisher
Jun 06, 2025

Squarepoint Ops LLC Has $398,000 Holdings in Neurogene Inc. (NASDAQ:NGNE) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Cuts Stake in Neurogene Inc. (NASDAQ:NGNE) - Defense World

Jun 05, 2025
pulisher
May 30, 2025

Neurogene Reports Q1 2025 Financial Progress and Updates - TipRanks

May 30, 2025
pulisher
May 26, 2025

Northern Trust Corp Buys 5,845 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World

May 26, 2025
pulisher
May 22, 2025

BMO Capital Markets Forecasts Strong Price Appreciation for Neurogene (NASDAQ:NGNE) Stock - Defense World

May 22, 2025
pulisher
May 21, 2025

Deutsche Bank AG Sells 181,997 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World

May 21, 2025
pulisher
May 20, 2025

Neurogene (NGNE) Receives Price Target Boost from BMO Capital | - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Neurogene (NGNE) Receives Price Target Boost from BMO Capital | NGNE Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Neurogene stock target raised to $22 by BMO Capital - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

ASGCT Roundup: Sarepta, Rocket, Neurogene and the World’s First Tailored CRISPR Therapy - NewsBreak: Local News & Alerts

May 19, 2025
pulisher
May 19, 2025

Neurogene introduces gene therapy monitoring system after patient death - Yahoo Finance

May 19, 2025
pulisher
May 18, 2025

Neurogene (NASDAQ:NGNE) Stock Rating Lowered by Robert W. Baird - Defense World

May 18, 2025
pulisher
May 18, 2025

Baird R W Downgrades Neurogene (NASDAQ:NGNE) to Hold - Defense World

May 18, 2025
pulisher
May 17, 2025

Neurogene presents HLH treatment strategy at ASGCT meeting By Investing.com - Investing.com Nigeria

May 17, 2025
pulisher
May 17, 2025

Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $46.20 - Defense World

May 17, 2025
pulisher
May 16, 2025

Neurogene Shares Drop After Downgrade From Baird - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday - Benzinga

May 16, 2025
pulisher
May 16, 2025

Neurogene stock downgraded at Baird (NGNE:NASDAQ) - Seeking Alpha

May 16, 2025
pulisher
May 16, 2025

Neurogene (NGNE) Downgraded to Neutral with Lowered Price Target | NGNE Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Neurogene (NGNE) Presents New Protocol for Tackling Gene Therapy - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Neurogene presents HLH treatment strategy at ASGCT meeting - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

Neurogene Announces Evidence-Based Monitoring And Treatment Intended To Reverse Rare Hyperinflammatory Syndrome Associated With High-Dose Aav - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Neurogene (NGNE) Presents New Protocol for Tackling Gene Therapy Complication | NGNE Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV - Eagle-Tribune

May 16, 2025
pulisher
May 16, 2025

Neurogene (NGNE) Downgraded by Baird Amid Regulatory Concerns | - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Baird cuts Neurogene stock rating, lowers price target to $24 By Investing.com - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

Neurogene (NGNE) Downgraded by Baird Amid Regulatory Concerns | NGNE Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Baird cuts Neurogene stock rating, lowers price target to $24 - Investing.com

May 16, 2025
pulisher
May 16, 2025

Q2 Earnings Estimate for Neurogene Issued By HC Wainwright - Defense World

May 16, 2025
pulisher
May 15, 2025

Rett Syndrome treatment Market Is Booming Worldwide 2025-2032 | - openPR.com

May 15, 2025
pulisher
May 15, 2025

HC Wainwright Has Lowered Expectations for Neurogene (NASDAQ:NGNE) Stock Price - Defense World

May 15, 2025
pulisher
May 13, 2025

Neurogene (NGNE) Analyst Rating Update: Target Price Adjusted | - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Neurogene (NGNE) Target Price Reduced, Buy Rating Maintained | N - GuruFocus

May 13, 2025

Neurogene Inc Azioni (NGNE) Dati Finanziari

Non sono disponibili dati finanziari per Neurogene Inc (NGNE). Controlla altri titoli per ulteriori informazioni.

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):